Trial Profile
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Aug 2022
Price :
$35
*
At a glance
- Drugs Cefepime/taniborbactam (Primary) ; VNRX-5022 (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors VenatoRx Pharmaceuticals
- 03 Aug 2022 Results published in the Antimicrobial Agents and Chemotherapy
- 21 Oct 2020 Results published in the VenatoRx Pharmaceuticals media release
- 21 Oct 2020 According to a VenatoRx Pharmaceuticals media release, data from this study will be presented at the IDWeek 2020.